Organ-confined muscle-invasive bladder cancer (MIBC) is treated with either radical cystectomy (RC) or radiotherapy (RT) and carries survival rates of only 40-60%. There is no clear survival advantage between the two therapies and therefore biomarkers that could aid in the choice of treatment would be of use in this disease. Both the abundance of the DNA repair protein, MRE11, and the genotype of a single nucleotide polymorphism in the MRE11 gene, have been found to have potential as predi...